Summary & Overview
HCPCS S9990: Services Provided as Part of a Phase II Clinical Trial
HCPCS Level II code S9990 denotes services provided as part of a phase II clinical trial and identifies patient care activities and monitoring associated with investigational treatments. Nationally, clear coding for clinical trial services is important for accurate claims processing, research reimbursement transparency, and distinguishing trial-related care from standard clinical services. This code helps payers and providers separate investigational service lines for coverage determinations and reporting.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what S9990 represents, the typical clinical settings where it is used, and the payer landscape that commonly interacts with this code. The publication also summarizes benchmarking considerations, common modifier usage patterns when present, and the clinical context for phase II trial services. Where input data is missing, the report notes unavailable elements rather than inferring specifics.
This summary is intended for billing managers, clinical research administrators, and policy analysts who need a concise national perspective on the role of S9990 in coding and reimbursement workflows for phase II clinical trial services.
Billing Code Overview
HCPCS Level II code S9990 represents services provided as part of a phase II clinical trial. The service type is clinical trial services, encompassing patient care activities, monitoring, and procedures that support investigational treatments during a phase II study. The typical site of service for S9990 is clinical trial settings, which may include hospital outpatient departments, physician offices, academic medical centers, and research clinics conducting phase II trials.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with advanced solid tumor enrolls in a Phase II clinical trial evaluating a novel targeted therapy. The patient presents to an academic oncology clinic for study-related visits that include protocol-directed assessments: baseline and on-treatment history and physical exams, collection of safety labs, administration of investigational drug under study-specific procedures, documentation of adverse events, and collection of research-specific specimens. Study coordinators schedule visits per protocol; the treating clinician documents medically necessary evaluations and determines continued study eligibility. Billing uses HCPCS Level II code S9990 to report services provided as part of the Phase II clinical trial when those services are distinct from standard-of-care and are billed to the study sponsor or as permitted by payer policy. Typical sites of service include hospital outpatient departments, physician offices, and freestanding cancer centers. Common scenarios include initial enrolment visit with informed consent and baseline testing, interim safety visits with physical exam and toxicity assessment, and end-of-treatment visits documenting response and disposition.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work or resources substantially exceed usual for a study-related service. |
| Unusual anesthesia | Use when medically necessary anesthesia is provided for a study procedure.